BioMarin intends to move into Phase 3 study discussions on the next stage of development with health authorities with a dose of 15 micrograms per kilogram daily. Also, a new cohort, designed to test a new dose regimen has completed enrollment for the Phase 2 study.

A new cohort for the phase 2 clinical trial for BMN-111 has been revealed, learn more about it here.

Recap on the results from the first 6 months of the phase 2 clinical trial for BMN-111, elicited by a presentation at the American Society for Bone and Mineral Research of 2015.

Soluble FGFR3, a drug for achondroplasia under development by TherAchon is moving towards clinical trials. See the summary of their press release here.

New potential treatment for achondroplasia being developed by BioClin Therapeutics. It's based on monoclonal antibodies and is also being tested for Urothelial Cell Carcinoma.

This is a summary of Dr. Tsumaki's lecture at the 12th ISDS meeting about statins as a potential treatment for achondroplasia.